Kotlinska-Lemieszek A, et al. - Given the raised risk of serious adverse effects and drug-drug interactions (DDIs) among patients with advanced malignant disease taking several drugs to control symptoms, researchers sought for studies reporting clinically significant drug-drug interactions (DDIs) involving medications used for symptom control, other than opioids used for pain management, in adult patients with advanced malignant disease. They retrieved 9699 citations and considered 462 of these as potentially eligible. After full-text reading, 29 together with 13 articles from reference lists were included in the final analysis. Antiepileptics, antidepressants, corticosteroids, and nonopioid analgesics were the most often involved drugs. DDIs manifested clinically as sedation, respiratory depression, serotonin syndrome, neuroleptic malignant syndrome, delirium, seizures, ataxia, liver and kidney failure, bleeding, cardiac arrhythmias, rhabdomyolysis, and others. Findings suggest a limited risk of clinically significant DDIs in these patients. However, physicians are recommended to limit polypharmacy, avoiding drug combinations with a high risk of DDIs, and closely monitoring patients for adverse drug reactions.